Table 1.

Patients’ series details (diagnosis, treatment response and follow-up data).

Patient	Sex	Age (years)	Disease status at Aza beginning	Karyotype	MDAPS	BM blasts (%)	ECOG	TD	Response	Aza cycles at response	Loss of response (months of response duration)	FU (months)	Status	Cause of death	Disease status at FU	Total Aza cycles at FU
1	M	83	AML	Normal	NA	30	2	Yes	NE	NA	NA	2	Death	MOF	NE	2
2	M	76	CMML-2 (MPR)*	Normal	Int-2	19	1	No	PR°°	6	No	19	Alive	NA	PR	13
3	M	72	CMML-1 (MPR) **	Normal	Low	3	1	No	SD°°	6	No	12	Death	Sudden cardiac death	SD	12
4	F	72	CMML-2 (MD) ***	Normal	Int-1	11	1	No	SD	4	No	27	Alive	NA	SD	20
5	M	80	CMML-1 (MD)	Normal	Int-1	8	0	Yes	PR	6	No	18	Alive	NA	PR	14
6	M	86	CMML-2 (MPR) *	Normal	Int-2	18	1	No	PR°°	6	No	16	Alive	NA	PR	12
7	M	75	AML	46, XY, Inv12	NA	30	1	Yes	CR	6	Yes (5)	13	Death	AML	AML	14
8	M	62	CMML-2 (MD)	Normal	High	16	1	No	CR	4	Yes (1)	8	Death	AML	AML	6
9	F	62	CMML-2 (MPR) *	Normal	Int-2	16	0	No	CR°°	6	No	10	Alive	NA	CR	9
10	M	82	CMML-2 (MD)	45, X, -Y	Int-2	12	1	Yes	CR	4	No	10	Alive	NA	CR	10

Aza: azacitidine; AML: acute myeloid leukemia; CMML: chronic myelomonocytic leukemia; MPR: myeloproliferative; MD: myelodysplastic; ECOG: Eastern Cooperative Oncology score, TD: transfusion dependence; NA: not applicable; NE: not evaluated; PR: partial response; SD: stable disease; CR: complete response; FU: follow-up; MOF: multi-organ failure.

^*Indication for treatment was high bone marrow blasts count (16–19%);

^**Indication for treatment was severe symptomatic thrombocytopenia;

^***Indication for treatment was severe symptomatic neutropenia;

°Response criteria: Responses were classified according to the modified IWG response criteria in myelodysplasia⁹ for MD-CMML and IWG consensus criteria for treatment response in myelofibrosis¹⁰ for MPR-CMML;

°°In MPR-CMML patients, ongoing cytoreductive treatment was discontinued at the moment of azacitidine start; no cytoreduction was added during treatment and at response assessment.